Key result
New anticoagulant agents are undergoing advanced clinical testing to address the limitations of heparin and warfarin in preventing and treating venous and arterial thromboembolism.
Answers are grounded in this paper and cite their sources.
This review discusses emerging anticoagulant drugs in advanced clinical testing for the prevention and treatment of venous and arterial thromboembolism.
The limitations of traditional anticoagulants, heparin and warfarin, have prompted the development of new anticoagulant drugs for prevention and treatment of both venous and arterial thromboembolism. After a brief review of thrombogenesis and its regulation, this study focuses on new anticoagulant agents in more advanced stages of clinical testing.
No takes yet. Share an insight, caveat, or question.
Bates et al. (2003) studied this question. New anticoagulant agents are undergoing advanced clinical testing to address the limitations of heparin and warfarin in preventing and treating venous and arterial thromboembolism.
Synapse has enriched 10 related papers. Consider them for comparative context: